Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas

Jozef Malysz, Patrick Erdman, Jeremy Klapper, Junjia Zhu, Michael Creer, Michael Bayerl

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

US Food and Drug Administration approval of brentuximab for treatment of CD30-positive relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. We studied CD30 expression in various types of previously unstudied aggressive B-cell lymphomas, including Burkitt lymphoma, high-grade follicular lymphoma, grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), DLBCL type posttransplantation lymphoproliferative disease, and primary mediastinal B-cell lymphoma. Background US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas. We evaluated CD30 expression in 116 cases of aggressive B-cell lymphomas diagnosed at Penn State Milton S. Hershey Medical Center between 2000 and 2012 with the purpose of assessing the benefit of treatment with brentuximab. Patients and Methods We studied CD30 expression in types of aggressive B-cell lymphomas not previously studied, including Burkitt lymphoma, high-grade (grade III) follicular lymphoma, mixed grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), posttransplantation lymphoproliferative disease large B-cell lymphoma, and primary mediastinal large B-cell lymphoma. Results CD30 expression was found in 37.5% of DLBCL and 46.2% of other non-DLBCL aggressive B-cell lymphomas. Conclusion Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene–driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

Original languageEnglish (US)
Pages (from-to)429-433
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume16
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

B-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Follicular Lymphoma
Lymphoma
Drug Approval
Burkitt Lymphoma
Mediastinal Diseases
Anaplastic Large-Cell Lymphoma
Therapeutics
Food
Hodgkin Disease
Oncogenes
Non-Hodgkin's Lymphoma

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{3b5da91b3fc54c26a65a4f95607d6b01,
title = "Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas",
abstract = "US Food and Drug Administration approval of brentuximab for treatment of CD30-positive relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. We studied CD30 expression in various types of previously unstudied aggressive B-cell lymphomas, including Burkitt lymphoma, high-grade follicular lymphoma, grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), DLBCL type posttransplantation lymphoproliferative disease, and primary mediastinal B-cell lymphoma. Background US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas. We evaluated CD30 expression in 116 cases of aggressive B-cell lymphomas diagnosed at Penn State Milton S. Hershey Medical Center between 2000 and 2012 with the purpose of assessing the benefit of treatment with brentuximab. Patients and Methods We studied CD30 expression in types of aggressive B-cell lymphomas not previously studied, including Burkitt lymphoma, high-grade (grade III) follicular lymphoma, mixed grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), posttransplantation lymphoproliferative disease large B-cell lymphoma, and primary mediastinal large B-cell lymphoma. Results CD30 expression was found in 37.5{\%} of DLBCL and 46.2{\%} of other non-DLBCL aggressive B-cell lymphomas. Conclusion Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene–driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.",
author = "Jozef Malysz and Patrick Erdman and Jeremy Klapper and Junjia Zhu and Michael Creer and Michael Bayerl",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.clml.2016.04.011",
language = "English (US)",
volume = "16",
pages = "429--433",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "8",

}

Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas. / Malysz, Jozef; Erdman, Patrick; Klapper, Jeremy; Zhu, Junjia; Creer, Michael; Bayerl, Michael.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 16, No. 8, 01.08.2016, p. 429-433.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas

AU - Malysz, Jozef

AU - Erdman, Patrick

AU - Klapper, Jeremy

AU - Zhu, Junjia

AU - Creer, Michael

AU - Bayerl, Michael

PY - 2016/8/1

Y1 - 2016/8/1

N2 - US Food and Drug Administration approval of brentuximab for treatment of CD30-positive relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. We studied CD30 expression in various types of previously unstudied aggressive B-cell lymphomas, including Burkitt lymphoma, high-grade follicular lymphoma, grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), DLBCL type posttransplantation lymphoproliferative disease, and primary mediastinal B-cell lymphoma. Background US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas. We evaluated CD30 expression in 116 cases of aggressive B-cell lymphomas diagnosed at Penn State Milton S. Hershey Medical Center between 2000 and 2012 with the purpose of assessing the benefit of treatment with brentuximab. Patients and Methods We studied CD30 expression in types of aggressive B-cell lymphomas not previously studied, including Burkitt lymphoma, high-grade (grade III) follicular lymphoma, mixed grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), posttransplantation lymphoproliferative disease large B-cell lymphoma, and primary mediastinal large B-cell lymphoma. Results CD30 expression was found in 37.5% of DLBCL and 46.2% of other non-DLBCL aggressive B-cell lymphomas. Conclusion Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene–driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

AB - US Food and Drug Administration approval of brentuximab for treatment of CD30-positive relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. We studied CD30 expression in various types of previously unstudied aggressive B-cell lymphomas, including Burkitt lymphoma, high-grade follicular lymphoma, grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), DLBCL type posttransplantation lymphoproliferative disease, and primary mediastinal B-cell lymphoma. Background US Food and Drug Administration approval of brentuximab vedotin for treatment of CD30-positive relapsed/refractory lymphomas, including classical Hodgkin lymphoma and anaplastic large cell lymphoma, initiated significant interest in researching CD30 expression in other therapy-resistant or relapsed lymphomas. We evaluated CD30 expression in 116 cases of aggressive B-cell lymphomas diagnosed at Penn State Milton S. Hershey Medical Center between 2000 and 2012 with the purpose of assessing the benefit of treatment with brentuximab. Patients and Methods We studied CD30 expression in types of aggressive B-cell lymphomas not previously studied, including Burkitt lymphoma, high-grade (grade III) follicular lymphoma, mixed grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), posttransplantation lymphoproliferative disease large B-cell lymphoma, and primary mediastinal large B-cell lymphoma. Results CD30 expression was found in 37.5% of DLBCL and 46.2% of other non-DLBCL aggressive B-cell lymphomas. Conclusion Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene–driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

UR - http://www.scopus.com/inward/record.url?scp=85008602501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008602501&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2016.04.011

DO - 10.1016/j.clml.2016.04.011

M3 - Article

C2 - 27521276

AN - SCOPUS:85008602501

VL - 16

SP - 429

EP - 433

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 8

ER -